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Abstract
Bietti’s crystalline dystrophy (BCD) is a rare, autosomal recessive retinal degen-
erative disease associated with mutations in CYP4V2. In this study, we describe
the genetic and clinical findings in 19 unrelated BCD patients recruited from
five international retinal dystrophy clinics. Patients underwent ophthalmic
examinations and were screened for CYP4V2 mutations by Sanger sequencing
and quantitative polymerase chain reaction (qPCR) copy number variation
screening. Eight CYP4V2 mutations were found in 10/19 patients, including
three patients in whom only monoallelic mutations were detected. Four novel
mutations were identified: c.604G>A; p.(Glu202Lys), c.242C>G; p.(Thr81Arg),
c.604+4A>G; p.(?), and c.1249dup; p.(Thr417Asnfs*2). In addition, we identi-
fied a heterozygous paternally inherited genomic deletion of at least 3.8 Mb,
encompassing the complete CYP4V2 gene and several other genes, which is
novel. Clinically, patients demonstrated phenotypic variability, predominantly
showing choroidal sclerosis, attenuated vessels, and crystalline deposits of vary-
ing degrees of severity. To our knowledge, our study reports the first heterozy-
gous CYP4V2 deletion and hence a novel mutational mechanism underlying
BCD. Our results emphasize the importance of copy number screening in BCD.
Finally, the identification of CYP4V2-negative patients with indistinguishable
phenotypes from CYP4V2-positive patients might suggest the presence of muta-
tions outside the coding regions of CYP4V2, or locus heterogeneity, which is
unreported so far.
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Introduction
Bietti crystalline dystrophy (BCD) (OMIM 210370) is
a rare retinal degenerative disease that is inherited
in an autosomal recessive pattern (Li et al. 2004).
First described in three patients by the Italian ophthal-
mologist Bietti (1937) in Rome, BCD is defined and char-
acterized by glistening crystalline deposits in the fundus
associated with atrophy of the retinal pigment epithelium
(RPE) and choroidal sclerosis (Bietti 1937; Rossi et al.
2013). Crystal deposits at the corneal limbus have also
been documented (Rossi et al. 2013). Clinically, patients
affected with BCD present between the second and fourth
decade of life with impaired vision, nyctalopia, and para-
central scotomas. Vision loss and concentric visual field
constriction continue progressively, often resulting in
severe visual impairment by the fifth or sixth decade (Li
et al. 2004; Lee et al. 2005).
BCD has been reported to be more prevalent in Asian
populations, although patients of European, Middle East-
ern, African, and North and South American origin have
also been documented (Hu 1987; Li et al. 2004). More-
over, it has been estimated that up to 3% of patients ini-
tially diagnosed with nonsyndromic retinitis pigmentosa
can be accounted for by BCD (Mataftsi et al. 2004). BCD
is known to be caused by mutations in the CYP4V2 gene,
localized on chromosome 4q35 (Li et al. 2004). Currently,
up to 57 mutations in CYP4V2 have been associated with
BCD; the majority are missense/nonsense mutations, as
well as several small insertions, deletions, and splicing
mutations (Li et al. 2004; Lee et al. 2005; Lin et al. 2005;
Shan et al. 2005; Wada et al. 2005; Jin et al. 2006; Lai
et al. 2007; Zenteno et al. 2008; Mamatha et al. 2011;
Xiao et al. 2011; Yokoi et al. 2011; Haddad et al. 2012;
Manzouri et al. 2012; Parravano et al. 2012; Song et al.
2013; Halford et al. 2014; Yin et al. 2014). CYP4V2
encodes a member of the cytochrome P450 superfamily,
characterized as a fatty acid oxidase involved in lipid
metabolism (Nakano et al. 2009). Surprisingly, evidence
of altered lipid metabolism has also been demonstrated in
fibroblasts and lymphocytes of patients with BCD, in
which synthesis of n-3 polyunsaturated fatty acids was
decreased (Lee et al. 2001). Crystalline deposits have also
been reported in these cells (Wilson et al. 1989). Further-
more, patients with BCD have been shown to have abnor-
mal serum fatty acid profiles, with increased stearic acid
and reduced oleic acid concentrations (Lai et al. 2010).
These findings suggest that BCD represents a systemic
condition that is not limited to the eye. However, it is
still unclear whether these systemic abnormalities are
actually disease-causing or whether they are subclinical
(Li et al. 2004). It has been hypothesized that the retinal
crystals represent lipids or fatty acids (Lai et al. 2010).
Finally, the phenotypic spectrum of CYP4V2 mutations
has been expanded to autosomal recessive retinitis pig-
mentosa (arRP), without intraretinal crystals being
observed in affected patients (Mataftsi et al. 2004).
In this study, we present novel genetic and clinical
findings in a large international cohort of 19 probands
from unrelated families with apparent Bietti crystalline
retinal dystrophy.
Materials and Methods
Subject enrolment and clinical evaluation
Nineteen patients were recruited from and evaluated at
the McGill Ocular Genetics Laboratory and Clinic at the
McGill University Health Centre, in Montreal Canada; the
Centre for Ophthalmology at the University of T€ubingen,
in Germany; the Ophthalmic Genetics Clinic at the Ghent
University Hospital, in Belgium; the Rare Retinal Disease
Centre (Siegburg Eye Center), Germany; and INSERM in
Montpellier, France. Informed consent was obtained and
research protocols adhered to the tenets of the Declaration
of Helsinki. Institutional Review Board (IRB)/Ethics Com-
mittee approval was obtained. Patients had histories and
pedigree analysis taken, and underwent ophthalmic exami-
nation including visual acuity (VA) testing, Goldmann
visual field testing, refraction, slit lamp examination,
dilated fundus examination, fundus photography, fundus
autofluorescence (FAF), optical coherence tomography
(OCT), and full-field flash electroretinography (ERG),
recorded in accordance with the guidelines of the Interna-
tional Society for Clinical Electrophysiology of Vision
(Marmor et al. 2009). One patient did not have Goldmann
visual field testing nor OCT testing. In addition, fluores-
cein angiography was also performed in two patients.
Phlebotomy in ethylenediaminetetraacetic acid tubes was
performed to collect venous blood for genetic studies.
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Mutation analysis
Homozygosity mapping (only performed in
Lebanese family A)
Genomic DNA was isolated from lymphocytes by stan-
dard salting out procedures (Miller et al. 1988). DNA
samples of all four affected individuals from family A
were genotyped on the GeneChip Genome-Wide Human
SNP Array 5.0 that contains 500,000 polymorphic SNPs
in addition to 420,000 nonpolymorphic probes for the
detection of germline copy number variations (CNVs)
(Affymetrix, Santa Clara, CA). Array experiments were
performed according to protocols provided by the manu-
facturer. The 5.0 array data were genotyped using Affyme-
trix Genotype Console (version 2.1), subsequently regions
of homozygosity were identified using Partek Genomics
Solution (version 6.1), as described previously (Collin
et al. 2011). Regions containing more than 250 consecu-
tive homozygous SNPs were considered as homozygous
regions, on average corresponding to a genomic size of
1 Mb or more.
Mutation analysis
All exons and intron–exon boundaries of CYP4V2
(NM_207352) were amplified under standard polymerase
chain reaction (PCR) conditions using primers listed in
Table S1. PCR products were purified on Nucleospin
Plasmid Quick Pure columns (Machery Nagel, D€uren,
Germany) and sequenced in sense and antisense direc-
tions with dye termination chemistry on a 3730 or 2100
DNA analyzer (Applied Biosystems, Carlsbad, CA).
Bioinformatic analysis and evolutionary
comparison for missense mutations
For each of the missense changes identified in this study,
the potential pathogenicity was assessed using online
prediction software tools SIFT (Sorting Intolerant from
Tolerant) and PolyPhen (Ng and Henikoff 2003). Gran-
tham and PhyloP scores were also determined. In addi-
tion, the Exome Variant Server database was checked for
the presence and minor allele frequencies of these novel
mutations. Four computational programs, SpliceSite fin-
der-like, MaxEntScan (Yeo and Burge 2004), NNSPLICE
(Reese et al. 1997), and Human Splicing Finder (Desmet
et al. 2009) were employed to predict the effect on the
canonical acceptor and donor splice sites.
CNV screening using qPCR and SNP chip arrays
CNV screening on genomic DNA was performed in the
families with only one CYP4V2 mutation (probands F, I,
and J), using 13 quantitative PCR (qPCR) assays, covering
Figure 1. Pedigrees of 10 families with Bietti
crystalline dystropy carrying mutations in
CYP4V2. Affected individuals are indicated
with filled symbols, whereas unaffected
relatives are indicated by open symbols. The
probands are indicated with an arrow and
slashed symbols indicate deceased. Mutated
alleles are indicated with M symbols and wild-
type allele with plus symbols.
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the 11 exons of CYP4V2 and two reference genes (ZNF80
and GPR15) on the LightCycler 480 (Roche, Basel,
Switzerland). Four controls were included in each experi-
ment. Conditions and primers can be found in Table S2.
Data analysis was performed using qBasePlus (Biogazelle,
Zwijnaarde, Belgium).
Genome-wide SNP chip analysis was performed using
the HumanCytoSNP-12 BeadChip platform (Illumina,
San Diego, CA) (proband F) in order to delineate the
deletion.
Results
Patient demographics and genotyping
In a consanguineous Lebanese family that was initially
diagnosed with atypical RP (Fig. 1A), genome-wide SNP
array analysis was combined with homozygosity map-
ping to identify genomic regions that could potentially
harbor the causative genetic defect. In total, only two
homozygous regions were identified that were identical
between the four affected siblings, one of which har-
bored the CYP4V2 gene, located on chromosome 4.
Sequence analysis revealed a homozygous missense
mutation in CYP4V2, c.332T>C; p. (Ile111Thr) that
completely segregated in the family (Fig. 1A). Most
notably, the proband presented with severe choroidal
sclerosis but no crystals were found on fundus examina-
tion. Upon further family examination, an affected
younger sibling, however, was noted to have diffuse
crystalline deposits in the fundus.
Subsequently, 18 additional patients were ascertained
that were diagnosed with retinal dystrophy and presented
or had presented with crystalline deposits. Sequence
Table 1. Mutation table.
Proband Type Allele 1 Allele 2
A Homozygous c.332T>C p.Ile111Thr c.332T>C p.Ile111Thr
B Homozygous c.604G>A p.Glu202Lys c.604G>A p.Glu202Lys
C Homozygous c.604+4A>G splicing c.604+4A>G Splicing
D Compound heterozygous c.802-8_810delinsGC Splicing c.1198C>T p.Arg400Cys
E Compound heterozygous c.242C>G p.Thr81Arg c.1198C>T p.Arg400Cys
F Compound heterozygous c.1249dup p.Thr417Asnfs*2 Genomic deletion Genomic deletion
G Compound heterozygous c.802-8_810delinsGC Splicing c.1198C>T p.Arg400Cys
H Homozygous c.1393A>G p.Arg465Gly c.1393A>G p.Arg465Gly
I Heterozygous c.332T>C p.Ile111Thr No second allele found
J Heterozygous c.802-8_810delinsGC splicing No second allele found
Table 2. Pathogenicity predictions for missense and splice site mutations based on in silico analyses.
Amino acid change predictions
DNA change Mutation consequence Exome variant server1 PhyloP Grantham score SIFT PolyPhen References
c.242C>G p.(Thr81Arg) – 2.55 71 Tolerated Benign Novel
c.332T>C p.(Ile111Thr) – 4.56 89 Deleterious Probably damaging Li et al. (2004)
c.604G>A p.(Glu202Lys) – 5.61 56 Deleterious Probably damaging Novel
c.1198C>T p.(Arg400Cys) 2/13004 MAF 0.0154 4.48 180 Deleterious Probably damaging Lai et al. (2007)
c.1393A>G p.(Arg465Gly) 2/13004 MAF 0.0077 1.25 125 Deleterious Probably damaging Rossi et al. (2013)
Splicing prediction
DNA change
Mutation
consequence Position SSF (0–100) MaxEnt (0–12) NNSPLICE (0–1) HSF (0–100) Reference
c.604+4A>G Altered splicing c.604 84.07 ⇒ 73.99 (12.0%) 8.95 ⇒ 4.29 (52.1%) 0.98 ⇒ 0 (100%) 92.33 ⇒ 83.99
(9.0%)
Novel
List of missense and splice site mutations identified in this study and predictions of their consequences with the use of in silico program (SIFT and
PolyPhen). Splicing prediction shows the percent decrease in comparison to the original splice donor site scores. In addition, HSF predicted a novel
splice donor site in position c.604+4. SIFT, sorting intolerant from tolerant; MAF, minor allele frequency; HSF, Human Splicing Finder; SSF, Splice
Sequence Finder; NNSPLICE, Splice Site Prediction by Neural Network.
1Heterozygous alleles of total number of chromosomes.
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analysis of all exons and intron–exon boundaries of
CYP4V2 in this cohort revealed nine more patients with
CYP4V2 mutations, four carrying apparent homozygous
mutations, three with compound heterozygous mutations,
and two individuals with only one heterozygous intragenic
variant (Fig. 1). All these patients were of Caucasian origin.
Patients with CYP4V2 mutations included seven
females and three males, with ages ranging between 33
and 77 years. Initially, eight different mutations in
CYP4V2 were identified, including four previously docu-
mented and four novel mutations. The novel mutations
were two missense, one splice site and one frameshift
mutation; namely c.604G>A; p.(Glu202Lys), c.242C>G;
p.(Thr81Arg), c.604+4A>G; p.(?), and c.1249dup;
p.(Thr417Asnfs*2) (Table 1). The novel missense muta-
tions were not observed in the comprehensive Exome
Variant Server database, while the already published
variants p.(Arg400Cys) and p.(Arg465Gly) have been
identified with low minor allele frequencies of 0.0154 and
0.0077, respectively. The most prevalent mutations identi-
fied in our cohort were the c.1198C>T; p.(Arg400Cys),
c.332T>C; p.(Ile111Thr), and c.802-8_810delinsGC; p.(?)
mutations, each accounting for 3 of the 18 mutant alleles
identified in the probands. We found the p. Arg400Cys
mutation in three patients, the p. Ile111Thr in two
patients, and the c.802-8_810delinsGC; p.(?) change in
three patients.
To evaluate the pathogenicity of the novel mutations,
in silico analysis using a variety of prediction programs
was performed. The two novel missense mutations,
p.(Thr81Arg) and p.(Glu202Lys), affect amino acid resi-
dues that are highly conserved among vertebrate species.
Both substitutions have a high Grantham score (Table 2).
Moreover, the p.(Glu202Lys) mutation, is predicted to be
Figure 2. Detection and delineation of a CYP4V2 deletion in proband F using qPCR and SNP-chip analysis. C (control), P (patient), WT (wild
type). (A) I and II: qPCR on proband F revealed a copy number of one for all 11 assays of CYP4V2, corresponding with a heterozygous total gene
deletion. The same was found for the other deleted genes; KLKB1 and F11. III: Demonstration of paternal origin of the deletion. (B) I: SNP-chip
analysis demonstrates deletion with size ~4 Mb, spanning the entire CYP4V2 gene and several other genes, two of which are OMIM genes
(KLKB1 and F11).
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pathogenic by the two in silico programs SIFT and Poly-
Phen (Table 2). The p.(Thr417Asnfs*2) frameshift muta-
tion is presumed to create a premature stop codon one
amino acid residue downstream, and in addition might
be targeted for nonsense-mediated decay (NMD). In silico
prediction of the c.604+4A>G splice site mutation showed
a decrease in the strength of the splice donor site due to
the alteration (e.g., 12% decrease in SpliceSite finder-like,
52% in MaxEntScan, 89.5% in NNSPLICE, and 9%
decrease in Human Splicing Finder [HSF]), suggesting
that this mutation might alter CYP4V2 splicing.
Upon assessing the segregation of mutations in avail-
able family members, an inconsistency was noted for pro-
band F, who carried an apparent homozygous mutation
c.1249dup; p.(Thr417Asnfs*2). The mutation was found
to segregate in the patient’s mother however not in her
father, while paternity was confirmed. Subsequently,
genomic qPCR analysis revealed a heterozygous deletion
encompassing all exons of CYP4V2, in both proband F
and her father (Fig. 2A). To further delineate the break-
points and determine the extent of this new deletion,
SNP-chip analysis was performed. The deletion size was
demonstrated to vary between 3.8 and 4.1 Mb, spanning
the entire CYP4V2 gene and several other genes, including
two OMIM genes (KLKB1 and F11) (Fig. 2B). No
CYP4V2 deletions were detected in the two other pro-
bands who carried a single heterozygous allele (data not
shown).
Patient phenotypes
The clinical data for all 10 patients that carried one or
two CYP4V2 alleles are described in Table 3. Disease
onset in these patients ranged from 18 to 57 years of age,
with duration of illness ranging from 8 to 33 years. Visual
acuities (VA) varied extensively and ranged from 20/20 to
light perception (LP), with large discrepancies in VA
between both eyes occasionally noted. With the exception
of three patients with no refractive error, all subjects wereTa
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Figure 3. Crystalline deposits seen on the lens (i) and corneal limbus
(ii) of 54-year-old proband D with compound heterozygous mutations
in CYP4V2 c.802-8_810delinsGC; p.(?), p.(Arg400Cys).
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myopic with astigmatism with refraction ranging from
0.50 to 6.00 dioptres. Goldmann visual fields also
revealed a wide spectrum of severity, ranging from rela-
tively normal to severe constriction (5–10° remaining).
Central, paracentral, and ring scotomas were also noted.
Crystalline deposits were noted in the corneal limbus of
three patients. In proband D, crystalline deposits were
seen on the lens as well as the limbus (Fig. 3). Posterior
subcapsular cataracts (PSCC) and cortical opacities were
noted in several patients.
The predominant findings on fundus examination
were extensive choroidal sclerosis, crystalline intraretinal
deposits, attenuated vessels, and intraretinal spicular pig-
mentation in varying degrees of severity (Fig. 4). Macular
atrophy was often seen. Of note is proband A, whose
fundus examination revealed choroidal sclerosis and
peripheral pigmentation but no crystal deposits. On
OCT, however, crystal deposits were observed in the sub-
retinal space (Figs. 4A and 5A). Proband J was similarly
reported to have a “choroideremia-like” fundus appear-
ance, with deposits seen in the subretinal layer on OCT.
Proband G was also noted to have an unusual fundus
appearance, consisting of large discoid patches of atrophy
separated by ridges of relatively intact tissue, along with
the presence of choroidal sclerosis and crystalline deposits
(Fig. 4G).
On OCT, two types of crystals were visualized in
patients – tiny intra- and inner retinal crystals and larger,
encapsulated subretinal crystals. All nine patients who
had OCT were noted to have fine inner retinal crystals;
five among these patients also showed larger subretinal
crystals (Fig. 5A, B, D, and E, no image available for pro-
band J). Foveal thinning and remodeling of retinal archi-
tecture were other pertinent findings. In addition, cystoid
macular edema (CME) was documented in two patients.
ERG was abnormal in all patients who underwent testing,
ranging from nonrecordable to subnormal photoreceptor
function.
Disease progression was noted in most patients for
whom previous clinical data were available, with declining
VA and visual fields. Progression of disease in the fundus of
proband F over 18 years was documented photographically
(Fig. 4F) and shows the development of the choroidal scle-
rosis and the clinical disappearance of the retinal crystals.
The clinical presentation of patients without identified
CYP4V2 mutations was indistinguishable from that of the
CYP4V2-positive patients. The phenotypes of five of the
CYP4V2-negative patients are shown in Figures S1 and
S2. These patients demonstrated the same severe changes
that were present in the patients with CYP4V2 mutations,
including choroidal show and sclerosis, the diffuse nature
of disease, bone spicules, and macular involvement with
or without crystalline deposits. OCT images similarly
reveal the fine inner retinal crystals as well as the larger
sometimes encapsulated subretinal crystals.
Discussion
We identified eight different CYP4V2 mutations in 10/19
patients in our cohort of crystalline retinal dystrophies,
clinically diagnosed as Bietti crystalline dystrophy. We
identified four novel mutations and one genomic rear-
rangement (deletion). This is the first large deletion
reported for BCD. Eight patients were found to have two
mutations in CYP4V2, while in two patients only one
mutation was detected, despite extensive analysis of the
coding region using Sanger sequencing and CNV analysis.
Until now, 57 mutations in CYP4V2 have been associated
with BCD. These include 43 missense/nonsense muta-
tions, eight splicing mutations, four small deletions, one
small insertion, and one small indel (Li et al. 2004; Lee
et al. 2005; Lin et al. 2005; Shan et al. 2005; Wada et al.
2005; Jin et al. 2006; Lai et al. 2007; Zenteno et al. 2008;
Mamatha et al. 2011; Xiao et al. 2011; Yokoi et al. 2011;
Haddad et al. 2012; Manzouri et al. 2012; Parravano et al.
2012; Song et al. 2013; Halford et al. 2014; Yin et al.
2014). To our knowledge, we are the first to identify a
deletion including CYP4V2 and several other genes in a
patient with BCD, expanding the molecular pathogenesis
of BCD. Interestingly, previous studies have reported five
patients in which only single heterozygous mutations were
found in CYP4V2, possibly implicating CYP4V2 CNVs as
found in proband F (Li et al. 2004; Shan et al. 2005; Jin
et al. 2006; Rossi et al. 2013).
The pathogenic role of CNVs and the importance of
their detection has been previously described in recessive
retinal dystrophies such as retinitis pigmentosa, Leber
congenital amaurosis (LCA), and cone dystrophy with
supernormal rod response (CDSRR) (Wissinger et al.
2011; Eisenberger et al. 2013). Ultimately, the detection of
such CNVs clarifies diagnosis, and may influence genetic
counseling. Our results demonstrate that CNV is a muta-
tional mechanism that can lead to BCD as well, and that
screening for such variations may be necessary to avoid
diagnostic uncertainties.
The deletion in proband F also covers two genes
KLKB1 and F11, both of which are involved in the con-
tact activated coagulation pathway. KLKB1 encodes
plasma prekallikrein – also known as Fletcher factor – a
glycoprotein in the kallikrein–kininogen–kinin system
(KKS) which participates in coagulation, fibrinolysis, and
inflammation. Plasma prekallikrein is converted to the
serine protease plasma kallikrein by factor XIIa through
cleavage of an internal Arg-Ile bond (Chung et al. 1986).
Kallikrein then cleaves both low- and high-molecular-
weight kininogens to release bradykinin and lys-bradyki-
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nin, mediating the effects of the KKS (Sainz et al. 2007).
Recessively inherited mutations in KLKB1 are known to
cause plasma prekallikrein deficiency, resulting in a pro-
longed activated partial thromboplastin time (aPTT)
without increased bleeding tendency in affected patients
(Lombardi et al. 2003). Heterozygous patients have been
reported to have decreased prekallikrein activity but nor-
mal aPTT values (Wynne Jones et al. 2004).
Figure 5. Optical coherence tomography images. Proband A: 57-year-old patient with homozygous mutations in CYP4V2 p.(Ile111Thr). Optical
coherence tomography shows severe foveal thinning and cystoid macular edema. Of note are two types of crystal that can be seen; tiny
intraretinal crystals and large encapsulated subretinal crystals (red arrows). Proband B: 67-year-old patient with homozygous mutations in CYP4V2
p.(Glu202Lys). Shown are remarkable thinning of the fovea and remodeling of retina, as well as presence of both intraretinal and subretinal
crystals. Proband C: 47-year-old patient with homozygous mutation in CYP4V2 c.604+4A>G; p.(?). Remodeling of retina with almost complete
loss of architecture is seen, as well as tiny intraretinal crystals. Proband D: 54-year-old patient with compound heterozygous mutations in CYP4V2
c.802-8_810delinsGC; p.(?), p.(Arg400Cys). Optical coherence tomography shows severe foveal thinning, remodeling of the retina, as well as
both intraretinal crystals and larger subretinal crystals. Proband E: A 41-year-old patient with compound heterozygous mutations in CYP4V2
p.(Thr81Arg), p.(Arg400Cys). Presence of both intraretinal and subretinal crystals. Photoreceptors in fovea remain intact. Proband F: 49-year-old
patient with homozygous mutations in CYP4V2 p.(Thr417Nfs*2). Optical coherence tomography shows fine intraretinal crystals. Proband I: 33-
year-old patient with one heterozygous mutation in CYP4V2 p.(Ile111Thr). Optical coherence tomography reveals presence of intraretinal crystals.
Figure 4. Fundus photographs. Proband A: 57-year-old patient with homozygous mutations in CYP4V2 p.(Ile111Thr). Fundus photograph shows
choroidal sclerosis and peripheral pigmentation. No crystal deposits are seen in this patient’s fundus. Proband B: 67-year-old patient with
homozygous mutations in CYP4V2 p.(Glu202Lys). Fundus photograph shows severe choroidal sclerosis involving the entire macula and fovea,
narrowing of the retinal vasculature, with relatively normal optic nerve appearance. Several crystalline deposits can be seen in the macula.
Proband C: 47-year-old patient with homozygous mutation in CYP4V2 c.604+4A>G; p.(?). Severe choroidal sclerosis and crystalline deposits in
macula. Proband D: 54-year-old patient with compound heterozygous mutations in CYP4V2 c.802-8_810delinsGC; p.(?), p.(Arg400Cys). Severe
choroidal sclerosis and area of visible sclera. Few crystalline deposits seen in midperiphery. Proband E: A 41-year-old patient with compound
heterozygous mutations in CYP4V2 p.(Thr81Arg), p.(Arg400Cys). Mild choroidal sclerosis, crystalline deposits, and pigment clump. Some
maculopathy is seen. Retinal vasculature remains relatively normal. Proband F: 49-year-old patient with homozygous mutations in CYP4V2
p.(Thr417Nfs*2). Fundus photographs show progression of disease in left eye (left to right). Of note is the progressive choroidal sclerosis, vascular
attenuation and decreasing presence of crystalline deposits over time. Photos taken at ages 31, 38, and 49, respectively. Proband G: 77-year-old
patient with compound heterozygous mutation in CYP4V2 c.802-8_810delinsGC; p.(?), p.(Arg400Cys). Unusual fundus appearance (left) showing
large, similarly-sized discoid patches of atrophy separated by small ridges of intact tissue with presence of crystals and choroidal sclerosis. Optic
disk and retinal vasculature appear relatively normal. Fundus autofluorescence (middle) confirms areas of atrophy with patches of decreased
autofluorescence surrounded by walls of lipofuscin metabolism. Proband H: 38-year-old patient with homozygous mutations in CYP4V2
p.(Arg465Gly). Choroidal sclerosis with diffuse crystalline deposits and pigment clumps in midperiphery. Proband I: 33-year-old patient with one
heterozygous mutation in CYP4V2 p.(Ile111Thr). Fundus photograph reveals nondescript retina with few crystalline deposits.
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Factor XI is a homodimeric glycoprotein that circulates
in plasma as a noncovalent complex with high-molecular-
weight kininogen (Fujikawa et al. 1986). Factor XI is
activated by factor XII, a-thrombin, and factor XI (autoac-
tivation); it participates in contact activated coagulation by
catalyzing the conversion of factor IX to factor IXa and
thereby sustaining thrombin generation (Naito and Fujika-
wa 1991). Factor XI deficiency (sometimes referred to as
“hemophilia C”) is a rare mild-to-moderate bleeding disor-
der associated with mutations in F11. Both autosomal
recessive and dominant modes of inheritance have been
described, the latter possibly being secondary to dominant-
negative mutations resulting in mutant proteins forming
nonsecretable heterodimers with wild-type subunits (Kravtsov
et al. 2004). Moreover, earlier studies demonstrated con-
siderable variability in rates of bleeding in heterozygotes,
with some studies even noting no distinction between
homozygotes and heterozygotes (Ragni et al. 1985; Bolton-
Maggs et al. 1988). Upon revisiting proband F’s medical
records, we found no history of coagulopathy.
In addition to the two patients in whom only single
mutations were detected, we failed to identify any
CYP4V2 mutations in nine other patients. The rate of
CYP4V2 mutation detection demonstrated in our study
was relatively low, especially when compared to a previ-
ous study by Xiao et al. (2011), in which CYP4V2 muta-
tions were found in >95% of BCD patient families (Xiao
et al. 2011). Our results suggest that CYP4V2 mutations
in our patients may reside in genomic locations that were
not studied in our gene sequencing protocol, that is, in
promoter, untranslated region, or deep intronic regions.
Alternatively our data suggests locus heterogeneity and a
second Bietti’s gene. We were able to re-examine five
CYP4V2-negative crystalline retinal dystrophy patients
and found that their phenotypes (Figs. S1, S2) are indis-
tinguishable from our BCD patients.
In accordance with previous studies, we found consid-
erable phenotypic variability in our cohort, with no obvi-
ous correlation of severity or features with patient
demographics. Although disease progression was noted in
most patients (for whom historical clinical data were
available), length of progression was not clearly associated
with a more severe phenotype. Previously, it has been
postulated that environmental factors affecting lipid
metabolism (e.g., diet) may also contribute to the spec-
trum of disease (Lee et al. 2005; Rossi et al. 2013). Signif-
icant clinical variability was also noted for patients
sharing common genotypes, and even within one family.
However, it can be observed that in general within our
cohort, those with genotypes resulting in splicing defects
or nonsense mutations (i.e., c.802-8_810delinsGC; p.(?),
c.604+4A>G; p.(?), and c.1249dup; p.(Thr417Asnfs*2))
demonstrated greater clinical severity. Notably, proband F
with the genomic deletion was documented to have one
of the most clinically severe phenotypes in our cohort. It
is possible that the heterozygous CYP4V2 deletion con-
tributes to her advanced disease state, however this
remains unclear as the patient was also found to have a
severe frameshift mutation.
Furthermore, proband E, with a mild phenotype
despite 21 years of disease, was found to have compound
heterozygous mutations, with one allele c.242C>G;
(p.Thr81Arg) predicted to be comparatively benign
(Table 2).
It should be noted, however, that these correlations
between mutation and disease severity have not been con-
sistently shown in previous studies; for instance, although
Lai et al. (2007) and Halford et al. (2014) document a
similar pattern, Rossi et al. (2013) note that this correla-
tion was not present in their patients. As well, two
patients (one with mutation c.1526C>T; (p.P509L) and
the other c.1393A>G; (p. p.R465G)) in whom only single
mutations were identified in previous studies failed to
show the same severity of disease as seen in proband F
(Jin et al. 2006; Rossi et al. 2013). The clinical features of
the three other heterozygous patients in the literature
were not described (Li et al. 2004; Shan et al. 2005).
In our patients, we documented four locations and
types of the crystals: small, widespread inner retinal crys-
tals; large, encapsulated subretinal crystals; corneal limbus
crystals; and lenticular crystals. The presence of encapsu-
lated subretinal crystals (in addition to inner retinal crys-
tals) on OCT has previously been reported (Pennesi and
Weleber 2013). Initially described by Zweifel et al. (2009)
in a series of patients with various retinal disorders, these
structures were termed “outer retinal tubulation.” How-
ever, a more recent study with BCD patients found that
the hyperrefractive structures identified were in fact
spherical (Kojima et al. 2012).
It is of note that proband D with compound heterozy-
gous mutations c.802-8_810delinsGC; p.(?) and c.1198C
>T; p.(Arg400Cys) was found to have crystalline deposits
on the lens, which is atypical for BCD. Two separate reports
of lenticular crystals have been documented previously,
with both patients described carrying the c.802-8_810delin-
sGC mutation as well, though in a homozygous state (Yo-
koi et al. 2010; Chung et al. 2013).
The phenotype of BCD is progressive and severe. In
the later stages, as retinal crystals become increasingly dif-
ficult to detect on clinical examination and disappear
with disease progression, the phenotype can overlap with
choroidal sclerosis and some phases of choroideremia; for
instance, as reported in the late-stage fundus appearance
of probands A and J (Mataftsi et al. 2004; Mansour et al.
2007; Xiao et al. 2011). It is therefore likely that when
patients are seen in the later stages of disease, a diagnosis
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of a nonspecific retinal dystrophy or atypical retinitis pig-
mentosa may be made. However, in both these patients
we documented that OCT reveals nevertheless the pres-
ence of retinal crystals. Our results therefore indicate that
OCT plays an essential role in the diagnosis and differen-
tiation of BCD from other retinal pathology presenting
primarily with choroidal sclerosis.
In conclusion, we identified four novel CYP4V2 muta-
tions in 10/19 BCD patients as well as the first genomic
rearrangement (large deletion) implicating CYP4V2. Our
results emphasize the importance of CNV screening in
BCD. Although the phenotype of the patient with the
CYP4V2 deletion was severe, no clear genotype–phenotype
correlation could be established. It would be interesting to
note what patterns emerge in future when more patients
with large deletions as such are reported. Finally, the nine
patients in whom no CYP4V2 mutations were found sug-
gest that CYP4V2 mutations may reside in genomic loca-
tions that were not covered by our protocol. Alternatively,
locus heterogeneity might underlie BCD; further investiga-
tions will follow to explore these possibilities.
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Figure S1. Fundus photographs of CYP4V2-negative
patients. Shown are fundus photographs of five CYP4V2-
negative Bietti crystalline dystrophy patients. As in those
with identified CYP4V2 mutations, predominant findings
include choroidal sclerosis with or without visible crystal-
line deposits, pigment deposition, and vascular attenua-
tion.
Figure S2. Optical coherence tomography images of
CYP4V2-negative patients. OCT images of five CYP4V2-
negative patients, with presence of small hyperreflective
intraretinal crystals and larger subretinal crystals (red
arrows).
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